key: cord-1006041-3tlg1iwf
authors: Guarino, Maria; Cossiga, Valentina; Esposito, Ilaria; Alessandro, Furno; Morisco, Filomena
title: Effectiveness of SARS-Cov-2 vaccination in liver transplanted patients: the debate is open!
date: 2021-08-03
journal: J Hepatol
DOI: 10.1016/j.jhep.2021.07.034
sha: ebd1cc8e227bb8354210ee7ad8e4568d9d10fd83
doc_id: 1006041
cord_uid: 3tlg1iwf

nan

Our results highlight the decreased humoral response in LT patients. Moreover, we define the most vulnerable individuals among them (i.e., older age, overweight/obese patients, multiple drug immunosuppression regimen and regimens including antimetabolites). Even if these findings were expected, given the known scarce antibody response to other vaccines in immunocompromised patients, we are continuing our study to obtain data about long-term effectiveness and immunogenicity of SARS-CoV-2 vaccine and the impact of an additional dose, as recently suggested by Werbel et al (5) .

CoV-2 vaccine.

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Effectiveness of SARS-CoV-2 vaccination in fullyvaccinated solid organ transplant recipients

Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series